الصفحة الرئيسية>>Signaling Pathways>> TGF-β / Smad Signaling>> ROCK>>ROCK2-IN-2

ROCK2-IN-2

رقم الكتالوجGC31883

ROCK2-IN-2 هو مثبط ROCK2 انتقائي مستخرج من براءة اختراع US20180093978A1 ، المركب A-30 ، يحتوي على IC50 أقل من 1 ميكرومتر

Products are for research use only. Not for human use. We do not sell to patients.

ROCK2-IN-2 التركيب الكيميائي

Cas No.: 1995065-79-6

الحجم السعر المخزون الكميّة
5mg
288٫00
متوفر
10mg
459٫00
متوفر
25mg
945٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ROCK2-IN-2 is a selective ROCK2 inhibitor extracted from patent US20180093978A1, Compound A-30, has an IC50 of <1 μM.

Rho-associated protein kinase (ROCK) is a member of the serine-threonine protein kinase family. ROCK, which exists in two isoforms, ROCK1 and ROCK2, is an effector molecule of RhoA, and the RhoA/ROCK signaling pathway is involved in a number of cellular functions, which include, for example, actin organization, cell adhesion, cell migration, and cytokinesis. In addition, the RhoA/ROCK signaling pathway is involved in regulating smooth muscle contraction. Inhibitors of ROCK have been reported to be useful for treating multiple medical disorders, such as fibrosis, inflammatory disorders, autoimmune disorders, and cardiovascular disorders[1].

[1]. Aicher, Thomas Daniel, et al. INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE. US20180093978A1.

مراجعات

Review for ROCK2-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ROCK2-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.